Clinical Trial Update: Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update examining idelalisib after allogeneic HSCT in B-cell malignancies; the study is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma of Bone
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2024-03-12